FACULTY
Steven Fishbane, MD
Chief of Nephrology
Northwell Health
New York, NY
Professor of Medicine
Zucker School of Medicine at Hofstra/Northwell
Long Island, NY
PROGRAM OVERVIEW
This case-based enduring activity will review the mechanisms of action and evidence-based standards of care in chronic kidney disease (CKD) and will benefit clinicians caring for patients with anemia associated with CKD.
LEARNING OBJECTIVES
At the completion of this activity, participants will be able to:
- Describe the complex pathophysiology of anemia of CKD, including the roles of inflammation, EPO, iron, hypoxia-inducible factor (HIF), and hepcidin.
- Discuss the advantages and disadvantages associated with evidence-based standard-of-care therapies for the management of anemia of CKD.
- Review the mechanisms of action and clinical profiles of emerging treatment options for the management of anemia of CKD, including those targeting hepcidin and HIF-prolyl hydroxylase.
TARGET AUDIENCE
This educational activity is specifically designed for US-based nephrologists and other healthcare professionals caring for patients with anemia associated with CKD.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .75 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses who diagnose, treat, and manage patients with anemia associated with CKD.
Credits: .75 ANCC Contact Hour(s)
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded .75 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Fishbane reports being a consultant with Akebia and AstraZeneca. Dr. Fishbane also reports that he has done contracted research for AstraZeneca, Fibrogen, and Gilead.
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
Matthew Frese, General Manager, of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development, for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation, for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator, for Med Learning Group has nothing to disclose.
Deborah Gordon, Medical Director, Scientific and Medical Services, for Med Learning Group has nothing to disclose.
Amanda Jenkins, Program Coordinator, for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, Dr. Fishbane may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete and submit the evaluation form to Med Learning Group.
You will receive your certificate after the enduring activity.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: March 24, 2021
EXPIRATION DATE: March 24, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
